# Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

> **NCT00135421** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 271 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Pexacerfont
- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00135421
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135421, "Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00135421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*